Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 7/2007

01-07-2007 | Brief Report

Infliximab treatment in two patients with psoriatic arthritis and secondary IgA nephropathy

Authors: Grigorios T. Sakellariou, Periklis Vounotrypidis, Charalampos Berberidis

Published in: Clinical Rheumatology | Issue 7/2007

Login to get access

Excerpt

IgA nephropathy is the most common form of glomerulonephritis worldwide and 15–40% of patients will eventually have end-stage renal disease [1]. IgA nephropathy can be primary (in most cases) or secondary. Its association with the seronegative spondyloarthropathies, mainly with ankylosing spondylitis and rarely with psoriatic arthritis (PsA), has been described [2]. This report describes two cases of IgA nephropathy associated with PsA and the effect of infliximab treatment for PsA on renal disease. …
Literature
1.
2.
Montenegro V, Monteiro RC (1999) Elevation of serum IgA in spondyloarthropathies and IgA nephropathy and its pathogenic role. Curr Opin Rheumatol 11:265–272PubMedCrossRef
3.
Veys EM, van Laere M (1973) Serum IgG, IgM and IgA levels in ankylosing spondylitis. Ann Rheum Dis 32:493–496PubMedCrossRef
4.
Ritchlin C, Haas-Smith SA, Hicks D, Cappuccio J, Osterland CK, Looney RJ (1998) Patterns of cytokine production in psoriatic synovium. J Rheumatol 25:1544–1552PubMed
5.
Ettehadi P, Greaves MW, Wallach D, Aderka D, Camp RD (1994) Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol 96:146–151PubMedCrossRef
6.
Lim CS, Yoon HJ, Kim YS, Ahn C, Han JS, Kim S et al (2003) Clinicopathological correlation of intrarenal cytokines and chemokines in IgA nephropathy. Nephrology 8:21–27PubMedCrossRef
7.
Chan LY, Leung JC, Tsang AW, Tang SC, Lai KN (2005) Activation of tubular epithelial cells by mesangial-derived TNF-alpha: glomerulotubular communication in IgA nephropathy. Kidney Int 67:602–612PubMedCrossRef
8.
Leung JC, Tang SC, Chan LY, Tsang AW, Lan HY, Lai KN (2003) Polymeric IgA increases the synthesis of macrophage migration inhibitory factor by human mesangial cells in IgA nephropathy. Nephrol Dial Transplant 18:36–45PubMedCrossRef
9.
Lan HY, Yang N, Nikolic-Paterson DJ, Yu XQ, Mu W, Isbel NM et al (2000) Expression of macrophage migration inhibitory factor in human glomerulonephritis. Kidney Int 57:499–509PubMedCrossRef
10.
Praga M, Gutierrez E, Gonzalez E, Morales E, Hernandez E (2003) Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol 14:1578–1583PubMedCrossRef
11.
Forshaw MJ, Guirguis O, Hennigan TW (2005) IgA nephropathy in association with Crohn’s disease. Int J Colorectal Dis 20:463–465PubMedCrossRef
12.
de Moura CG, de Moura TG, de Souza SP, Testagrossa L (2006) Inflammatory bowel disease, ankylosing spondylitis, and IgA nephropathy. J Clin Rheumatol 12:106–107PubMedCrossRef
13.
Yamamoto M, Yorioka T, Kawada M, Nishimura K, Kumon Y, Yasuoka N et al (1994) A case of IgA nephropathy associated with psoriasis vulgaris. Nippon Jinzo Gakkai Shi 36:779–783PubMed
Metadata
Title
Infliximab treatment in two patients with psoriatic arthritis and secondary IgA nephropathy
Authors
Grigorios T. Sakellariou
Periklis Vounotrypidis
Charalampos Berberidis
Publication date
01-07-2007
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 7/2007
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-006-0422-z

Other articles of this Issue 7/2007

Clinical Rheumatology 7/2007 Go to the issue

Case report

Purtscher’s-like retinopathy as an initial presentation of adult-onset Still’s disease: a case report and review of the literature

Brief Report

CPPD complicating other forms of inflammatory arthritis

Original Article

Endothelial functions are more severely impaired during active disease period in patients with Behcet’s disease

Brief Report

Combination therapy with cyclosporine A and anti-TNF-α agents in the treatment of rheumatoid arthritis and concomitant hepatitis C virus infection

Case Report

A rare disorder: idiopathic tumoral calcinosis

Case Report

Bilateral spontaneous pneumothorax in a patient with pulmonary rheumatoid nodules, secondary infected by Aspergillus
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits